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BACKGROUND: Gene expression profiling has divided diffuse large B-cell lymphoma (DLBCL) into 2 main subgroups: ger-
minal center B (GCB) and non-GCB type. This classification is reproducible by immunohistochemistry using specific anti-
bodies such as CD10, B-cell lymphoma 6 (BCL6), and multiple myeloma oncogene 1 (MUM1). Fine-needle aspiration (FNA)
plays an important role in the diagnosis of non-Hodgkin lymphoma, and in some cases FNA may be the only available
pathological specimen. The objectives of the current study were to evaluate CD10, BCL6, and MUM1 immunostaining on
FNA samples by testing the CD10, BCL6, and MUM1 algorithm on both FNA cell blocks (CB) and conventional smears
(CS), evaluating differences in CB and CS immunocytochemical (ICC) performance, and comparing results with histologi-
cal data. METHODS: Thirty-eight consecutive DLBCL cases diagnosed by FNA were studied. Additional passes were used
to prepare CB in 22 cases and CS in 16 cases; the corresponding sections and smears were immunostained using CD10,
BCL6, and MUM1 in all cases. The data obtained were compared with histological immunostaining in 24 cases. RESULTS:
ICC was successful in 33 cases (18 CB and 15 CS) and not evaluable in 5 cases (4 CB and 1 CS). The CD10-BCL6-MUM1
algorithm subclassified DLBCL as GCB (9 cases) and non-GCB (24 cases). ICC data were confirmed on histologic staining
in 24 cases. CONCLUSIONS: CD10, BCL6, and MUM1 ICC staining can be performed on FNA samples. The results herein
prove it is reliable both on CB and CS, and is equally effective and comparable to immunohistochemistry data. Cancer
(Cancer Cytopathol) 2016;124:135-43. VC 2015 American Cancer Society.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL); it may
arise de novo or from the transformation of a former NHL, and accounts for approximately 40% of NHL
cases.1,2 DLBCL is a heterogeneous disease with a variable clinical course, and patients currently are treated with
a combination of immunotherapy and chemotherapy.3 The clinical presentation and outcome are remarkably
variable, reflecting biologic and pathogenetic heterogeneity.4 On the basis of gene expression profiling (GEP),
DLBCL can be divided into distinct subgroups that differ in terms of molecular features and reflect the origin
from different stages of B-cell differentiation during germinal center maturation.5 This classification based on the
cell of origin divides DLBCL into at least 3 different groups: the germinal center B cell-like (GCB), the activated
B cell-like (ABC), and the unclassifiable DLBCL. This subclassification appears to have prognostic and predictive
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value, because patients with ABC and unclassifiable DLBCL
have worse overall survival compared with patients with
GCB DLBCL and respond less effectively to the current
therapeutic regimens; an overall cure rate of approximately
40% is reported.4,6 GEP may not be used in routine clinical
practice because of high costs and the need for specific tech-
nologies; therefore, different immunohistochemical (IHC)
algorithms have been proposed within the last decade to
classify DLBCL subgroups by means of specific phenotypic
profiles.7–13 These algorithms include various antibodies,
with CD10, B-cell lymphoma 6 (BCL6), and multiple
myeloma oncogene 1 (MUM1) being the most frequently
used.7–10 The combination of CD10, BCL6, and MUM1
may classify DLBCL into GCB DLBCL and non-GCB
DLBCL (ABC and unclassified subgroup), with approxi-
mately 80% concordance with GEP.3,7
Fine-needle aspiration (FNA) plays an important role
in the diagnosis and management of NHL and may repre-
sent the only source of diagnostic material in specific clini-
cal contexts.14 Therefore, an accurate FNA diagnosis with
prognostic/predictive information is advisable, with or with-
out subsequent histological examination. Immunocyto-
chemical (ICC) assessment is commonly used in FNA on
different cytological samples, such as conventional smears
(CS), cytospin preparations, ThinPrep, and cell blocks
(CB), with different fixation of the samples and varying
procedures.15–18 Because the 2 institutions involved in the
current study routinely use CB and CS, respectively, for
ICC, this difference was examined to assess whether there
might be differences in terms of ICC performance.
The objectives of the current study were the evalua-
tion of CD10, BCL6, and MUM1 ICC on FNA samples;
testing of the CD10-BCL6-MUM1 algorithm on FNA
CB and CS preparations; and identification of differences
in CS and CB ICC performance in comparison with histo-
logical data.
MATERIALS AND METHODS
A prospective study of DLBCL FNA was performed at the
cytopathology services of the university hospitals of the
“Federico II” University of Naples and the University of
Salerno, both in Italy. The study design was approved by
the Campania Sud Ethics Committee (cometicocampania-
sud@asl3sud.it). Forty-one consecutive DLBCL cases,
diagnosed by FNA over a 2-year period (January 2013-
December 2014), were retrieved from the files of the 2
institutions. Three of these cases had been histologically
diagnosed as high-grade follicular lymphoma and were
not considered in the current study, leaving 38 proven
DLBCL cases.
FNA Procedures and Enrollment Criteria
FNA and enrollment criteria were similar in the 2 institu-
tions. FNA procedures and related risks were discussed
with patients and informed consent was obtained. FNA
generally was performed with a 23-gauge needle under
ultrasound guidance, with the exception of 2 axillary
lymph nodes that were aspirated under direct palpation
and 1 para-aortic lumbar lymph node in which a
22-gauge, 20-cm long Chiba needle was used with a probe
adaptor. In all the cases, rapid on-site evaluation (ROSE)
of Diff-Quik-stained smears was performed to evaluate the
adequacy of the sample and for a primary diagnosis.
Flow Cytometry Procedure
A second pass was flushed in phosphate-buffered saline
and used for flow cytometry (FC) analysis using the follow-
ing fluoresceinated antibodies: CD3, CD5, CD19, CD23,
FMC7, and CD10; kappa and lambda light chains; and a
3-color analysis technique on a Becton Dickinson FACS
scan (BD Biosciences, San Jose, Calif) as previously
described.19,20 FC was considered not effective (NE) when
fluoresceinated antibodies, including those targeting light
chains, were not expressed or evaluable.19,21 When DLBCL
was suspected at the time of ROSE, additional passes were
then flushed in 5 mL of buffered formalin to prepare
paraffin-embedded CB using the Shandon Cytoblock CB
preparation system (Thermo Fisher Scientific, Waltham,
Mass), according to the manufacturer’s instructions; alter-
natively, 3 additional CS were fixed in 95% alcohol for
ICC analysis. CB were used to analyze 22 cases and CS
were used in 16 cases.
ICC Procedure
An ICC study was performed on 4-mm sections of dew-
axed and dehydrated formalin-fixed, paraffin-embedded
CB and on alcohol-fixed CS. After heat-induced antigen
retrieval, slides were processed using the BenchMark
Autostainer (Ventana Medical Systems Inc, Tucson, Ariz)
using the iVIEW 3,3’-diaminobenzidine detection kit
(Ventana Medical Systems Inc) according to the manufac-
turer’s instructions. The following prediluted monoclonal
antibodies were used in all cases: CD10 (clone SP67;
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Ventana), BCL6 (clone GI191/A8; Cell Marque Corpora-
tion, Rocklin, Calif), and MUM1 (clone MRQ-43; Cell
Marque Corporation). CD3, CD15, CD30, and ALK-1
were also used in 4 cases, in which a differential diagnosis
of T-cell lymphoma, Hodgkin lymphoma (HL), and
anaplastic (ALK-1 positive or negative) lymphoma was
considered.
Evaluation Criteria for ICC
To determine CD10, BCL6, and MUM1 expression,
ICC evaluation was performed through the identifica-
tion of nuclear (BCL6 and MUM1) or cytoplasmic
(CD10) membrane positivity. According to the litera-
ture,7,11,13,22 the corresponding antibodies were consid-
ered positive when expressed in at least 30% of the
diagnostic cells. Smaller or indeterminate DLBCL cells
were not considered in cell counting; only large and
definitively atypical DLBCL cells were incorporated
into the count. ICC was considered NE when insuffi-
cient cells were present on the CB or none of the cells
on the CS was immunostained, and negative when
DLBCL cells were not immunostained, apart from
background positivity (namely granulocytes, medium-
sized follicular center cells, occasional stromal cells, and
plasma cells). The intensity of the signal was not con-
sidered.7,11,13,22 For ICC evaluation on CB sections,
routine histological or hematopathological samples
were used as positive controls and tested with the same
antibodies during the same IHC run. Negative controls
were obtained by omitting the primary antibody. With
regard to CS, negative and positive cells in the back-
ground of the corresponding smears were used as inter-
nal controls. Quantification was then performed by
counting the number of positive cells in 5 to 10 fields at
3430 high-power fields. Cases were then classified as
positive, negative, and NE for the corresponding anti-
bodies. The cases from each institution were blindly
and reciprocally reviewed by 2 of the authors (I.C. and
P.Z), who confirmed the original diagnoses, ICC
evaluation, and quantification. The data obtained
were compared with the histological data in 24 of 38
cases. To evaluate ICC performance on FNA DLBCL,
a linear regression analysis was performed between
ICC and IHC data on the 24 cases by plotting the 6
possible combinations generated by the expression of
CD10, BCL6, and MUM1 in a scatter plot graph. The
six categories are the following: 1) CD10-, BCL6-,
Figure 1. (A) Cytological features of diffuse large B-cell lym-
phoma (DLBCL) showing large isolated cells with an irregular
nuclear shape; small lymphocytes are present in the back-
ground. Note the expression of nuclear fragility indicated by
the nuclear strips (Diff-Quik stain, 3430). (B) DLBCL smear
showing large irregular nuclei with coarse, granular, dispersed
chromatin and 1 nucleoli; erythrocytes and small lympho-
cytes are present in the background (Papanicolaou stain,
3430). (C) Cell block appearance of DLBCL showing large,
isolated, irregular cells with dispersed chromatin and large
nucleoli (Papanicolaou stain, 3430).
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MUM11; 2) CD101, BCL6-, MUM1-; 3) CD101,
BCL61, MUM1-; 4) CD10-, BCL6-, MUM1-;
5) CD10-, BCL61, MUM1-; 6) CD10-, BCL61,
MUM11.
RESULTS
FNA samples from 38 DLBCL cases were used. Lymph
nodes were lateral cervical in 18 cases, inguinal in 8 cases,
submandibular in 5 cases, supraclavicular in 4 cases, axil-
lary in 2 cases, and para-aortic lumbar in 1 case. The male-
to-female ratio was 20:18, and the median age of the
patients was 62.4 years (range, 36-91 years). DLBCL
smears were generally highly cellular. The predominant
cell population was represented by large isolated cells with
irregular nuclear membranes and coarse, granular chroma-
tin with an overall pale appearance when compared with
small lymphoid cells (Figs. 1A-1C). One or 2 large,
Figure 2. Immunostaining with CD10, B-cell lymphoma 6 (BCL6), and multiple myeloma oncogene 1 (MUM1) in diffuse large B-cell
lymphoma cell blocks. In positive cases, >30% of the diagnostic cells show nuclear (BCL6 and MUM1) and cytoplasmic (CD10)
positivity. In negative cases, occasional diagnostic cells or small cells in the background represent positive internal controls
(CD10-BCL6-MUM1 immunostain, 3430). - indicates negative; 1, positive.
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irregular, eccentric nucleoli were often present (Figs. 1B
and 1C). Cytoplasm was thin, often ill-preserved, and
occasionally completely absent, giving the cells the appear-
ance of naked large nuclei. Nuclear fragility was often pres-
ent, with nuclear disruption or strips observed when
compared with cell integrity in the background (Figs. 1A
and 1B) of small and medium-sized lymphocytes, granulo-
cytes, occasional eosinophils, and macrophages. In 2 cases
with scant diagnostic cells and relatively numerous eosino-
phils, the differential diagnosis of HL was considered. In
such cases (cases 12 and 35), ICC for CD15 and CD30
on the CB and CS was negative, thus excluding the diag-
nosis of HL. In another 2 cases with more marked nuclear
atypia (cases 25 and 22), the differential diagnosis with
anaplastic lymphoma or T-cell NHL was considered and
excluded by FC and by CD30 and ALK ICC negativity,
Figure 3. Immunostaining with CD10, B-cell lymphoma 6 (BCL6), and multiple myeloma oncogene 1 (MUM1) in diffuse large B-cell
lymphoma conventional smears. In positive cases, >30% of the diagnostic cells show nuclear (BCL6 and MUM1) and cytoplasmic
(CD10) positivity. In negative cases, occasional diagnostic cells or small cells in the background represent positive internal con-
trols (CD10-BCL6-MUM1 immunostain, 3430). - indicates negative; 1, positive.
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respectively. FC was effective in 26 cases, demonstrating
the following phenotypes: CD191/CD5-/CD10-/CD23-/
FMC7- in 10 cases; CD191/CD5-/CD101/CD23-/
FMC7- in 11 cases; CD191/CD5-/CD101/CD23-/
FMC71 in 2 cases; and CD191/CD5-/CD10-/CD23-/
FMC71 in 3 cases. Kappa and lambda light chain restric-
tion was observed in 18 and 8 cases, respectively. In 12
cases in which FC was NE, the FNA diagnosis of DLBCL
was basically morphological and confirmed by the clinical
history in cases of DLBCL recurrence; by using CD3,
CD15, CD30, and ALK in selected cases; by the CD10-
BCL6-MUM1 algorithm; and by the follow-up histological
controls when available. Therefore, the diagnosis of
DLBCL was performed on the basis of morphological,
cytological, FC, and ICC data. Histological controls were
available in 24 of 38 cases, and confirmed the FNA diagno-
sis of DLBCL in 24 cases. Eight cases were DLBCL recur-
rences, which had been previously diagnosed histologically.
At the time of recurrence, the FNA diagnosis was consistent
with the clinical presentation, and histology was not
required by clinicians. In case 20 (para-aortic lymph node)
and cases 10 and 29 (patients aged 85 years and 91 years,
respectively), lymph nodes were not removed for the histo-
logical evaluation for clinical reasons and because the FNA
diagnosis matched with the clinical data. Finally, cases 2,
21, and 32 were histologically confirmed at other institu-
tions, but IHC data were not available for the algorithm
evaluation. ICC for CD10, BCL6, and MUM1 was suc-
cessfully performed on 18 CB and 15 CS, and was NE in
5 cases (Figs. 2 and 3). ICC combinations were CD10-/
BCL6-/MUM11 (20 cases), CD101/BCL6-/MUM1-
(1 case), CD101/BCL61/MUM1- (8 cases), CD10-/
BCL6-/MUM1- (2 cases), CD10-/BCL61/MUM1-
(1 case), and CD10-/BCL61/MUM11 (1 case) (Figs. 2
and 3). The CD10-BCL6-MUM1 algorithm classified
DLBCL as GCB in 9 cases (27%; 2 CB and 7 CS) and
non-GCB in 24 cases (73%; 16 CB and 8 CS). The histo-
logical controls confirmed the ICC data in 23 of the 24
available IHC cases, being discordant in only 1 case (case 6)
that was found to be negative for BCL6 on CB and positive
on IHC lymph node section. NE ICC results were reported
in 4 CB cases and 1 CS case (Table 1). No significant dif-
ferences were detected in terms of ICC quality when com-
paring ICC performance on CS and CB; the higher
number of NE findings among CB in comparison with CS
(4 cases vs 1 case) were caused by the scant cellularity of CB
sections in the corresponding cases.
The linear regression analysis obtained by grouping
the 6 combinations of CD10, BCL6, and MUM1 expres-
sion and plotting the ICC against the corresponding IHC
revealed a correlation coefficient value equal to 0.9819,
thus demonstrating a strong concordance between ICC
versus IHC data (Fig. 4).
DISCUSSION
Using the CD10-BCL6-MUM1 ICC algorithm applied to
CS and CB, we were able to subclassify DCBLC into GCB
and non-GCB in a series of 38 lymph node FNA cases.
The original algorithm proposed by Hans et al7 was based
on the expression of CD10, BCL6, and MUM1 and was
effective in the classification of DLBCL with a GEP con-
cordance in approximately 80% of the cases. Additional
studies have proposed other antibodies (such as BCL2,
Ki-67, and human leukocyte antigen [HLA])8–12 or new
antibodies (such as Forkhead box-P [FoxP], GCET1 (cen-
terin),22 and LMO210,13) to be used in addition to the 3
original ones (CD10, BCL6, and MUM1) or by replacing
BCL6.23,24 The algorithm by Choi et al22 introduced the
germinal center B cell-expressed transcript 1 (GECT1) as
the first discriminator of DLBCL cells, and FOXP1 as a
discriminator of CD10-/BCL61 cases achieving a 93%
concordance with GEP. In other recently proposed algo-
rithms, BCL6 was replaced by BCL224 or included CD10,
GCET, FOXP1, and MUM1 antibodies, which appear to
be the most specific for GCB and non-GCB, respectively.25
Figure 4. Immunocytochemistry (ICC)/immunohistochemistry
(IHC) scatter plot graph. The graph shows a scatter plot of 6
ICC immunophenotypes plotted versus the corresponding
IHC immunophenotypes among 24 patients analyzed. The
correlation coefficient value of 0.9819 revealed a strong con-
cordance between ICC and IHC data.
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The most recently proposed algorithm by Visco et al10
based on the expression of CD10, FOXP1, GCET-1,
MUM1, and BCL610 gained a 92.6% concordance with
GEP. All the proposed algorithms have advantages and lim-
itations, and none appears to dramatically improve either
the DLBCL subclassification or the concordance with
GEP. Moreover, in terms of predictive implications, the
retrospective evaluation of patients treated with different
protocols might determine different biologic behaviors and
survival rates in individuals affected by the same DLBCL
subtype (GCB or non-GCB).11,25 The CD10-BCL6-
MUM1 algorithm, as originally proposed,7 may classify
DLBCL into GCB and non-GCB (ABC and unclassifi-
able), with approximately 80% concordance with GEP.7
The new algorithms suggested in the literature,10,22,25 such
as the algorithm by Visco et al,10 might improve the con-
cordance with GEP significantly, but such algorithms
require the use of antibodies that are not used routinely.
The use of cytological material, which is quantita-
tively limited by definition, necessitates a more limited
number of antibodies. We chose CD10, BCL6, and
MUM1, which are available and routinely used in our lab-
oratories. Moreover, CD10, BCL6, and MUM1 were rou-
tinely tested on the corresponding histological data with
the same procedure. FNA is generally used as the first diag-
nostic step or in the follow-up of lymph node and extra
lymphoproliferative processes, and it is followed by histo-
logical examination in the majority of cases. Therefore, an
accurate cytological subclassification of DLBCL might be
considered to an objective that goes beyond the limits of
TABLE 1. Clinical and Phenotypic Classification of 38 Cases of DLBCL Diagnosed by FNA
Case No. Localization Age, Years Sex CB/CS CD10 BCL6 MUM1 DLBCL Subtype
Histological
Concordance
1 Left lateral cervical 43 F CB - - 1 Non-GCB Yes
2 Bilateral lateral cervical 66 F CB - - 1 Non-GCB Yesa
3 Right submandibular 47 F CB - - 1 Non-GCB Yes
4 Right lateral cervical 49 M CB NE NE NE NP NA
5 Left supraclavicular 52 F CB - - 1 Non-GCB Yes
6 Left lateral cervical 46 F CB 1 - - GCB No BCL61
7 Left lateral cervical 80 F CB - - 1 Non-GCB NA
8 Left supraclavicular 55 F CB - - 1 Non-GCB NA
9 Left supraclavicular 68 F CB - - - Non-GCB Yes
10 Left lateral cervical 85 M CS NE NE NE NP NA
11 Left inguinal 72 M CB 1 1 - Non-GCB NA
12 Right lateral cervical 77 M CB - - 1 Non-GCB Yes
13 Right lateral cervical 55 M CS - - 1 Non-GCB Yes
14 Right lateral cervical 43 M CB NE NE NE NP NA
15 Right lateral cervical 65 F CS 1 1 - GCB NA
16 Right submandibular 76 M CS 1 1 - GCB Yes
17 Left inguinal 81 M CS - - 1 Non-GCB Yes
18 Right inguinal 58 F CS 1 1 - GCB Yes
19 Right lateral cervical 49 M CS - - 1 Non-GCB Yes
20 Para-aortic lumbar 72 M CB NE NE NE NP NA
21 Right inguinal 51 F CS 1 1 - GCB Yesa
22 Left supraclavicular 66 F CB - - 1 Non-GCB Yes
23 Left lateral cervical 69 M CB - 1 - GCB Yes
24 Left axillary 69 M CB - 1 1 Non-GCB Yes
25 Left submandibular 39 F CB - - 1 Non-GCB Yes
26 Left lateral cervical 60 M CB - - 1 Non-GCB Yes
27 Left axillary 69 M CB - - - Non-GCB Yes
28 Left inguinal 54 F CB - - 1 Non-GCB Yes
29 Left lateral cervical 91 M CB - - 1 Non-GCB NA
30 Left lateral cervical 65 M CS - - 1 Non-GCB NA
31 Right submandibular 76 M CS 1 1 - GCB Yes
32 Left lateral cervical 72 F CS 1 1 - GCB Yesa
33 Left lateral cervical 53 M CS - - 1 Non-GCB Yes
34 Left submandibular 62 M CB NE NE NE NP NA
35 Left inguinal 36 M CS - - 1 Non-GCB Yes
36 Left lateral cervical 53 F CS - - 1 Non-GCB Yes
37 Right inguinal 65 F CS 1 1 - GCB Yes
38 Right inguinal 81 F CS - - 1 Non-GCB Yes
Abbreviations: -, negative; 1, positive; BCL6, B-cell lymphoma 6; CB, cell block; CS, conventional smear; DLBCL, diffuse large B-cell lymphoma; F, woman;
FNA, fine-needle aspiration; GCB, germinal center B; M, man; MUM1, multiple myeloma oncogene 1; NA, not available; NE, not effective; NP, not performed.
a Not available for immunohistochemistry algorithm.
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FNA. Nonetheless, in specific clinical situations, FNA may
be the only diagnostic procedure, and the diagnosis of
DLBCL with an accurate subclassification may be useful,
providing additional clinical information. The main diffi-
culties in DLBCL subclassification on FNA samples
include the management of the diagnostic material, the
choice of an effective and limited panel of antibodies, and
the interpretation of cytological results and their reproduci-
bility when compared with histological data.
In our experience, as well as the experience of
others,15,26 the management of diagnostic material is deter-
mined by ROSE. In fact, after the routine preparation of
CS and cell suspension for FC, when DLBCL was consid-
ered in the differential diagnosis, additional passes and
residual material were used to prepare CB and additional
CS for ICC assessment. DLBCL diagnostic cells are often
intermingled with other inflammatory, nonlymphomatous
cells; as a result, antigen expression has to be evaluated in
relation to the cytological features. Therefore, ICC, per-
formed either on CS or CB, was appropriate for compar-
ing the obtained results with the histological data and was
the ancillary technique used for the current study. The
panel of CD10, BCl6, and MUM1 was chosen because it
was specific and available in both institutions, as well as in
all the IHC controls, and left extra material for further
diagnostic tests. In this respect, CD3, CD15, CD30, and
ALK were initially tested in 4 cases to exclude T-cell NHL;
HL; and anaplastic, ALK1 lymphoma, respectively, and
diagnostic material was still available to include corre-
sponding cases in the current study. When the final FNA
diagnosis of DLBCL was achieved, the corresponding CB
and CS were tested by the CD10-BCl6-MUM1 algorithm.
As reported earlier, ICC was successful in 33 of the 38
cases and classified as positive or negative for the corre-
sponding antibodies. ICC was NE in 5 of the 38 cases (in
4 CB due to the lack of cells and in 1 CS because of defec-
tive fixation). The same criteria were used to evaluate histo-
logical data, and a general concordance was achieved
between FNA data and the 24 cases of corresponding his-
tological data. Moreover, in the current series, CD10 and
MUM1 expression were mutually exclusive, helping to dis-
tinguish between the GCB and non-GCB samples.
The results of the current study suggest that the
CD10-BCL6-MUM1 ICC algorithm may be hampered
mainly by insufficient cells on CB but, when performed, is
effective and reproducible when compared with histologi-
cal data. With regard to CB and CS efficacy as a technical
support for ICC, CS appears to be more effective than CB
because of the possible scant cellularity of the latter, being
ICC quality equally effective on CB and CS. The clinical
value of the DLBCL classification is not accepted unani-
mously, and the current series was too small to have any
clinical and predictive value. However, we believe it is large
enough to assess the reproducibility of the algorithm when
compared with the corresponding histological data.
The CD10-BCL6-MUM1 ICC algorithm is reliable
for FNA specimens and equally effective on CB and CS,
with cell adequacy being the main technical limitation.
Therefore, ICC data are comparable to the histological
data. FNA subclassification of DLBCL may provide addi-
tional prognostic information that might be useful when
histological data are not available.
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